Descrizione del progetto
Proteine della membrana del guscio d’uovo utilizzate per la guarigione di ferite croniche
Le ferite croniche, quali ulcere delle gambe, ulcere da decubito e ulcere del piede diabetico, sono ferite che non guariscono entro un periodo di tre mesi oppure ferite che guariscono senza ripristinare l’integrità funzionale. Oltre ai tempi di recupero, che vanno da anni a decenni, i pazienti sperimentano dolore acuto, disagio emotivo e limitazioni nella mobilità. Questo progetto, finanziato dall’UE, lavorerà sulla convalida clinica e sulla produzione commerciale dell’innovativa medicazione per ferite DermaRep, sviluppata di recente dall’azienda Biovotec. Isolato dalla membrana del guscio d’uovo e facilmente accessibile, questo prodotto rivoluzionario potrebbe diventare un nuovo punto di riferimento nella guarigione delle ferite, abbassando nel contempo gli ingenti costi necessari per il trattamento di ferite croniche.
Obiettivo
A chronic wound (such as Leg Ulcer (LU), Pressure Ulcer (PU) and Diabetic Foot Ulcer (DFU) can be defined as one that has failed to proceed through an orderly and timely reparative process to produce anatomic and functional integrity within a period of 3 months or that has proceeded through the repair process without establishing a sustained and anatomic and functional result. Chronic wounds may require several years to heal, and some remain unhealed for decades. During this time, patients can experience severe pain, significant emotional and physical distress, reduced mobility and social isolation.
LU, PU and DFU are a major healthcare cost for all developed countries. The main driver for growth in cost is the treatment of chronic and complex wounds in the aging population, complicated by the increase in diabetes and other metabolic disorders. LUs account for $50Bn of global wound care burden in 2015 and are to reach $53Bn in 2020. DFUs account for $52Bn – and are to reach $56Bn by 2020. Further, PUs account for $41Bn of global wound care burden in 2015 – and are to reach $47Bn by 2020.
We have developed an innovative wound dressing, DermaRep™, that is based on biomaterial derived from Eggshell Membrane (ESM) – a by-product readily available in the egg industry. The purified form of ESM is called Purified Eggshell Membrane Protein (PEP).
DermaRep™ is disruptive and will become the benchmark in the wound healing market as it directly addresses the healthcare needs by providing a novel wound care product that is significantly more effective than current Standard of Care (SoC, relatively non-expensive silicon, foam and hydrocolloid dressings) and at least as effective as existing State of the Art (SoA) collagen-based dressings.
Campo scientifico
Programma(i)
Argomento(i)
Meccanismo di finanziamento
IA - Innovation actionCoordinatore
0275 OSLO
Norvegia
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.